Estimating The Number of Relapsed And Refractory Indolent Lymphoma Patients Across Europe, Who Are Expected To Initiate A New Line of Therapy (LOT)
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.123
https://www.valueinhealthjournal.com/article/S1098-3015(17)30457-6/fulltext
Section Title :
Disease-Specific Studies
Section Order :
104
First Page :
A418
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30457-6&doi=10.1016/j.jval.2017.08.123